| KKR & CO INC. |
| USA |
| Finanzen |
| US48251W1045 / A2LQV6 |
| KR51 (Frankfurt) / KKR (NYSE) |
| FRA:KR51, ETR:KR51, KR51:GR, NYSE:KKR |
| - |
| https://www.kkr.com/ |
|
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address dis..
>Volltext.. |
| 77225.46 Mio. EUR |
| 152398.71 Mio. EUR |
| 20488.56 Mio. EUR |
| 4918.47 Mio. EUR |
| 2744.37 Mio. EUR |
| 2.92 EUR |
| 48037.48 Mio. EUR |
| 18460.37 Mio. EUR |
| 8033.15 Mio. EUR |
| 1.44 |
| 35.98% |
| 58.57% |
| 0.65 EUR |
| 0.77% |
| 0.8% |
| 10.08.26 - 0.1688895€ 15.05.26 - 0.167661€ >weitere anzeigen... |
| KKR & CO, KOHLBERG KRAVIS, KKR |
| 22.09.26 |